
CGEM Valuation
Cullinan Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
CGEM Relative Valuation
CGEM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGEM is overvalued; if below, it's undervalued.
Historical Valuation
Cullinan Therapeutics Inc (CGEM) is now in the Fair zone, suggesting that its current forward PS ratio of 68.82 is considered Fairly compared with the five-year average of -7.02. The fair price of Cullinan Therapeutics Inc (CGEM) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:8.18
Fair
-2.45
PE
1Y
3Y
5Y
Trailing
Forward
-0.87
EV/EBITDA
Cullinan Therapeutics Inc. (CGEM) has a current EV/EBITDA of -0.87. The 5-year average EV/EBITDA is -5.14. The thresholds are as follows: Strongly Undervalued below -30.85, Undervalued between -30.85 and -18.00, Fairly Valued between 7.72 and -18.00, Overvalued between 7.72 and 20.58, and Strongly Overvalued above 20.58. The current Forward EV/EBITDA of -0.87 falls within the Historic Trend Line -Fairly Valued range.
-0.84
EV/EBIT
Cullinan Therapeutics Inc. (CGEM) has a current EV/EBIT of -0.84. The 5-year average EV/EBIT is -4.44. The thresholds are as follows: Strongly Undervalued below -23.59, Undervalued between -23.59 and -14.02, Fairly Valued between 5.14 and -14.02, Overvalued between 5.14 and 14.71, and Strongly Overvalued above 14.71. The current Forward EV/EBIT of -0.84 falls within the Historic Trend Line -Fairly Valued range.
68.82
PS
Cullinan Therapeutics Inc. (CGEM) has a current PS of 68.82. The 5-year average PS is 40.27. The thresholds are as follows: Strongly Undervalued below -77.16, Undervalued between -77.16 and -18.44, Fairly Valued between 98.99 and -18.44, Overvalued between 98.99 and 157.70, and Strongly Overvalued above 157.70. The current Forward PS of 68.82 falls within the Historic Trend Line -Fairly Valued range.
-2.56
P/OCF
Cullinan Therapeutics Inc. (CGEM) has a current P/OCF of -2.56. The 5-year average P/OCF is -8.07. The thresholds are as follows: Strongly Undervalued below -28.72, Undervalued between -28.72 and -18.40, Fairly Valued between 2.25 and -18.40, Overvalued between 2.25 and 12.57, and Strongly Overvalued above 12.57. The current Forward P/OCF of -2.56 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Cullinan Therapeutics Inc. (CGEM) has a current P/FCF of 0.00. The 5-year average P/FCF is -6.21. The thresholds are as follows: Strongly Undervalued below -26.72, Undervalued between -26.72 and -16.47, Fairly Valued between 4.04 and -16.47, Overvalued between 4.04 and 14.30, and Strongly Overvalued above 14.30. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Cullinan Therapeutics Inc (CGEM) has a current Price-to-Book (P/B) ratio of 0.87. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -23.68% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about -35.35% higher. Cullinan Therapeutics Inc (CGEM) has a Forward Free Cash Flow (FCF) yield of approximately -30.56%. Compared to its 3-year average FCF yield of -24.87%, the current FCF yield is approximately 22.88% lower. Relative to its 5-year average FCF yield of -18.23% , the current FCF yield is about 67.59% lower.
0.87
P/B
Median3y
1.14
Median5y
1.35
-30.56
FCF Yield
Median3y
-24.87
Median5y
-18.23
Competitors Valuation Multiple
The average P/S ratio for CGEM's competitors is 24.88, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM) exhibits a P/S ratio of 68.82, which is 176.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CGEM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CGEM in the past 1 year is driven by Unknown.
People Also Watch

AUTL
Autolus Therapeutics PLC
2.510
USD
-0.40%

DNTH
Dianthus Therapeutics Inc
22.280
USD
+3.63%

WEST
Westrock Coffee Co
7.160
USD
+0.85%

KRT
Karat Packaging Inc
28.200
USD
0.00%

UPB
Upstream Bio Inc
14.340
USD
+5.21%

CMP
Compass Minerals International Inc
20.430
USD
+0.29%

CTLP
Cantaloupe Inc
11.080
USD
0.00%

IRWD
Ironwood Pharmaceuticals Inc
0.799
USD
-2.08%

CTO
CTO Realty Growth Inc
17.340
USD
-1.76%

ZJK
ZJK Industrial Co Ltd
3.490
USD
-2.51%
FAQ

Is Cullinan Therapeutics Inc (CGEM) currently overvalued or undervalued?
Cullinan Therapeutics Inc (CGEM) is now in the Fair zone, suggesting that its current forward PS ratio of 68.82 is considered Fairly compared with the five-year average of -7.02. The fair price of Cullinan Therapeutics Inc (CGEM) is between to according to relative valuation methord.

What is Cullinan Therapeutics Inc (CGEM) fair value?

How does CGEM's valuation metrics compare to the industry average?

What is the current P/B ratio for Cullinan Therapeutics Inc (CGEM) as of Jul 28 2025?

What is the current FCF Yield for Cullinan Therapeutics Inc (CGEM) as of Jul 28 2025?

What is the current Forward P/E ratio for Cullinan Therapeutics Inc (CGEM) as of Jul 28 2025?
